AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail.
阿斯利康和第一三共的datopotamab deruxtecan获得美国FDA的快速通道指定，用于治疗先前接受过全身治疗的晚期或转移性非鳞状非小细胞肺癌患者。
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, received US FDA Fast Track designation for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior systemic therapy. The designation is based on the TROPION-Lung01 Phase III trial, which showed a significant improvement in progression-free survival compared to standard chemotherapy.
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail. It strengthens AstraZeneca and Daiichi Sankyo's position in the competitive ADC market for oncology.
此信号在行业全局中的位置。
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.astrazeneca.com/media-centre/press-releases/2026/datopotamab-deruxtecan-granted-fast-track-designation-in-us-for-metastatic-non-small-cell-lung-cancer.html
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录